Dr. Leonardo Mirandola is the new Chief Scientific Officer of Kiromic biopharma
- Kiromic BioPharma (NASDAQ:KRBP) appoints Leonardo Mirandola, Ph.D., as Chief Scientific Officer, effective immediately.
- Dr. Mirandola has served as the Company’s Vice President of R&D and Clinical Translation since September 2021 and his previous role was Head of Clinical Translation from 2020 to 2021.
- He joined the company in 2016 as Executive Director of R&D.
Recommended For You
Comments
Have a tip? Submit confidentially to our News team. Found a factual error? Report here.